GMAB GENMAB A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 · USD | FY2024*2024-12-31 · USD | FY2023*2023-12-31 · USD | FY2019*2019-12-31 · DKK | FY2018*2018-12-31 · DKK |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.72B | $3.12B | $2.39B | 5.37B | 3.02B |
| Cost of revenue | $238.00M | $143.00M | $33.00M | — | — |
| Gross profit | $3.48B | $2.98B | $2.36B | — | — |
| R&D expense | $1.61B | $1.41B | $1.11B | 2.39B | 1.43B |
| SG&A expense | $626.00M | $549.00M | $478.00M | 342.00M | 214.00M |
| Operating income | $1.06B | $972.00M | $772.00M | 2.64B | 1.38B |
| Interest expense | $269.00M | $291.00M | $254.00M | 7.00M | 11.00M |
| Pretax income | $1.20B | $1.33B | $817.00M | 2.86B | 1.61B |
| Income tax | $241.00M | $193.00M | $186.00M | 693.00M | 140.00M |
| Net income | $963.00M | $1.13B | $631.00M | 2.17B | 1.47B |
| EBITDA | — | — | — | 2.68B | 1.41B |
| EPS (basic) | 15.50 | 17.66 | 9.67 | 34.40 | 24.03 |
| EPS (diluted) | 15.37 | 17.53 | 9.58 | 34.03 | 23.73 |
| Weighted avg. shares (diluted) | 62.69M | 64.66M | 65.90M | 63.64M | 62.04M |
| Balance sheet | |||||
| Cash & equivalents | $1.72B | $1.38B | $2.20B | 3.55B | 533.00M |
| Receivables | $1.11B | $923.00M | $733.00M | 2.99B | 1.33B |
| Inventory | $18.00M | $9.00M | $8.00M | — | — |
| Current assets | $2.88B | $3.90B | $4.91B | 13.96B | 7.43B |
| PP&E, netmay include right-of-use assets (IFRS) | $153.00M | $137.00M | $142.00M | 237.00M | 162.00M |
| Goodwill | $355.00M | $355.00M | $0 | — | — |
| Intangibles | $9.12B | $1.73B | $15.00M | 470.00M | 470.00M |
| Total assets | $12.87B | $6.41B | $5.23B | 15.14B | 8.46B |
| Current liabilities | $1.43B | $744.00M | $368.00M | 938.00M | 444.00M |
| Short-term debt | $273.00M | $0 | $0 | — | — |
| Long-term debt | $5.00B | $0 | $0 | — | — |
| Total debt | $5.27B | $0 | $0 | — | — |
| Total liabilities | $7.03B | $1.28B | $545.00M | 1.10B | 447.00M |
| Shareholders' equity | $5.85B | $5.14B | $4.69B | 14.05B | 8.01B |
| Net debt | $3.56B | -$1.38B | -$2.20B | — | — |
| Shares outstanding | 64.24M | 66.19M | 66.07M | 65.07M | 61.50M |
| Cash flow statement | |||||
| Operating cash flow | $1.19B | $1.13B | $1.07B | 1.33B | 1.01B |
| Capital expenditure | $37.00M | $27.00M | $53.00M | 79.00M | 72.00M |
| Free cash flow | $1.15B | $1.10B | $1.02B | 1.25B | 943.00M |
| Investing cash flow | -$5.64B | -$1.45B | -$185.00M | -1.98B | -1.78B |
| Financing cash flow | $4.79B | -$566.00M | -$89.00M | 3.66B | -71.00M |
| Depreciation & amortization | — | — | — | 40.00M | 28.00M |
| Stock-based compensation | $128.00M | $105.00M | $85.00M | 147.00M | 91.00M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.